WallStSmart

Cardio Diagnostics Holdings Inc (CDIO)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Revolution Medicines Inc generates 5035% more annual revenue ($742,000 vs $14,450). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).

CDIO

Avoid

23

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 6.5
Piotroski: 2/9Altman Z: -1.93

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CDIOUndervalued (+40.5%)

Margin of Safety

+40.5%

Fair Value

$2.22

Current Price

$2.03

$0.19 discount

UndervaluedFair: $2.22Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CDIO2 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

CDIO4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.01M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.8x4/10

Trading at 16.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : CDIO

The strongest argument for CDIO centers on Price/Book, Debt/Equity.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : CDIO

The primary concerns for CDIO are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

CDIO carries more volatility with a beta of 2.23 — expect wider price swings.

CDIO is growing revenue faster at -28.3% — sustainability is the question.

CDIO generates stronger free cash flow (-1M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RVMD scores higher overall (24/100 vs 23/100). CDIO offers better value entry with a 40.5% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cardio Diagnostics Holdings Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Cardio Diagnostics Holdings Inc (CDIO) is a pioneering biotechnology firm focused on enhancing cardiovascular health through innovative diagnostic solutions. The company utilizes state-of-the-art technology to equip healthcare professionals with vital tools for precise assessment and management of cardiovascular diseases, thereby improving patient outcomes. With a commitment to personalized medicine and a robust growth strategy, CDIO stands out as an attractive investment opportunity for institutional investors seeking to capitalize on advancements in the dynamic healthcare sector.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?